Company Overview

Biofrontera AG is a German biopharmaceutical company focused on dermatology, with an emphasis on the treatment of non-melanoma skin cancers and chronic skin conditions. The company develops and commercializes prescription drugs and medical devices, primarily in the field of photodynamic therapy (PDT). Its core business centers on the commercialization of aminolevulinic acid-based therapies used for actinic keratosis, a precancerous skin condition caused by long-term sun exposure. Biofrontera operates within the broader pharmaceutical, dermatology, and medical technology industries.

The company’s primary revenue drivers include sales of its PDT drug products and associated medical lamps used during treatment procedures. Its flagship product, Ameluz®, has been approved in multiple jurisdictions for actinic keratosis treatment and certain forms of basal cell carcinoma when used with PDT. Biofrontera’s customer base primarily includes dermatologists, dermatology clinics, and healthcare providers across Europe and North America. The company was founded in 1997 in Germany and evolved from a biotechnology research-focused organization into a commercially oriented dermatology company with international operations. Biofrontera has sought to differentiate itself through specialized expertise in PDT and a combination of pharmaceutical and device-based treatment offerings.

Business Operations

Biofrontera conducts operations through several commercial and development-focused entities, including Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, and U.S.-based subsidiaries supporting commercialization activities. The company generates revenue primarily through product sales, licensing arrangements, and distribution partnerships. Its principal commercial products include Ameluz®, a prescription topical gel used in PDT procedures, and the BF-RhodoLED® lamp platform designed to activate the drug during treatment. The company also markets products related to acne and other dermatologic indications in certain markets.

Operations are concentrated in Europe and the United States, with the U.S. market representing a strategically important commercial region due to dermatology procedure volumes and reimbursement frameworks. Biofrontera maintains intellectual property related to formulation technologies and PDT applications. Historically, the company has engaged in distribution and commercialization partnerships to expand market access internationally. Public disclosures also indicate ongoing clinical development activities intended to broaden approved indications for existing products.

Strategic Position & Investments

Biofrontera’s strategic direction has focused on expanding the commercial reach of Ameluz®, increasing physician adoption of PDT therapies, and pursuing additional regulatory approvals for dermatological indications. The company has invested in clinical studies aimed at expanding label indications and strengthening reimbursement positioning in key markets. Strategic emphasis has also been placed on enhancing direct commercial operations in the U.S. dermatology market.

The company has pursued investments in product lifecycle management, intellectual property protection, and medical device integration associated with PDT treatment systems. Biofrontera has also explored opportunities in adjacent dermatology applications involving light-activated therapies. Publicly available filings and investor materials identify ongoing efforts to strengthen operational efficiency and optimize commercial infrastructure. Information regarding certain long-term strategic outcomes and future market expansion plans remains subject to evolving market conditions and regulatory developments.

Geographic Footprint

Biofrontera is headquartered in Leverkusen, Germany, and maintains operations across multiple international markets. The company has established a notable presence in Germany, other parts of Europe, and the United States through subsidiaries, distribution relationships, and direct commercial activities. The U.S. market has become increasingly significant to overall operations due to demand for dermatological treatments and procedural dermatology services.

The company’s products have received approvals in several jurisdictions, including parts of the European Union and the United States, supporting international commercialization efforts. Biofrontera’s operational footprint includes research, regulatory, manufacturing coordination, and sales functions distributed across these regions. Its market influence remains concentrated in developed healthcare markets with established dermatology infrastructure.

Leadership & Governance

Biofrontera AG operates under a German corporate governance structure consisting of a Management Board and Supervisory Board. Leadership has historically emphasized scientific specialization in dermatology, regulatory execution, and commercialization of PDT technologies. The company’s governance framework follows German public company standards applicable to listed corporations.

Key executives and leadership figures publicly associated with the company include:

• Hermann Lübbert – Founder and former Chief Executive Officer
• Thomas Schaffer – Chief Executive Officer
• Maximilian Schmedding – Chief Financial Officer
• Andreas Mück – Chief Operations Officer

Leadership communications and public filings indicate a strategic focus on expanding dermatology market penetration, improving commercial execution, and advancing PDT-related therapeutic applications. Certain executive appointments and governance roles have changed over time based on company filings and corporate announcements.